

Lao PDR

Support for Vaccine: Measles Rubella This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Lao PDR						
2. Vaccine grant number:	1720-LAO-18e-X						
3. Date of Decision Letter:	7-Jun-19						
4. Date of the Partnership Framework Agreement:	7-Jun-13						
5. Programme title:	New Vaccine Support (NVS), MR, 2D Routine						
6. Vaccine type:	Measles Rubella						
7. Requested product presentation and formulation of vaccine:	Measles Rubella, 10 dose(s) per vial, LYOPHILISED						
8. Programme Duration:¹	2018-2020						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2018	2019	2020	2021	2022	2023	Total ²
Programme Budget (US\$)	161,500	208,500	107,000	-	-	-	477,000
10. Vaccine introduction grant	Not applicable						
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						
Type of supplies to be purchased with Gavi funds	2018	2019					2020
Number of vaccine doses		319,800					-
Annual Amounts (US\$)	161,500	208,500					-
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
14. Self-procurement:	Not applicable						
15. Co-financing obligations:	According to the co-financing policy, the Country falls within the group:						Accelerated transition phase

¹This is the entire duration of the Programme.

²This is the total amount endorsed by Gavi for the entire duration of the Programme.

³This is the total amount approved by Gavi.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019	2020	2021	2022	2023
Number of vaccine doses	258,100	443,500	-	-	-
Number of AD syringes	177,700	296,600	-	-	-
Number of re-constitution syringes	28,400	48,800	-	-	-
Number of safety boxes	2,300	3,825	-	-	-
Value of vaccine doses (US\$)	165,140	283,808	-	-	-
Total co-financing payments (US\$) (including freight)	178,000	305,000	-	-	-

16. Operational support for catch-up campaigns:

Not applicable

17. Additional Reporting Requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock, by end of March; Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2019 15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

18. Financial clarifications:

Not applicable

19. Other conditions:

Not applicable

Signed by,

On behalf of Gavi



Hind Khatib-Othman

Managing Director, Country Programmes

7 June 2019